Cagrilintide and CagriSema: reading the REDEFINE 1 results

Cagrilintide and CagriSema are related terms, but they identify different things in a research discussion. CagriSema refers to the combination of cagrilintide and semaglutide. Evidence about that combination needs to stay attached to it.

The comparison in REDEFINE 1

The 2025 REDEFINE 1 paper reported a 68-week phase 3a trial in 3,417 adults with overweight and an obesity-related complication, or obesity, without diabetes. Groups received the combination, either component alone, or placebo, alongside lifestyle interventions.

For the combination versus placebo, the reported estimated mean weight change was a reduction of 20.4% versus 3.0%. Gastrointestinal adverse events were common. Novo Nordisk funded the study. These are trial findings, not instructions for combining products independently.

Keep the combination attached to the result

When someone quotes the combination's result as if it describes cagrilintide alone, a step has gone missing. The study's separate treatment groups let readers investigate that distinction rather than assuming every number applies to every ingredient mentioned.

A useful note-taking format is simple: write the treatment name exactly as the paper uses it, then the comparator, then the outcome. This makes it harder to accidentally turn a combination result into a claim about one component.

Check how the analysis treats interruptions

The paper reports a treatment-policy estimand, an analysis approach intended to assess the effect of assignment while accounting for treatment discontinuation or other events as specified in the trial plan. Before comparing its headline with another paper, check whether the other analysis is asking the same question.

You do not need to master every statistical term to notice a difference. Flag unfamiliar language and use the paper's explanation, rather than replacing it with the biggest number in a social post.

What to look for next

Separate this publication from later studies, regulatory decisions, and information about a particular product. A named trial has a fixed design and reporting date; a development program continues to change.

For another example of a comparison built within one trial, read our SURMOUNT-5 guide. The question in both cases is which result belongs to which treatment, population, and follow-up period.